PROSPECTIVE CONTROLLED TRIAL OF ORAL KANAMYCIN IN PREVENTION OF NEONATAL NECROTIZING ENTEROCOLITIS
PROSPECTIVE CONTROLLED TRIAL OF ORAL KANAMYCIN IN PREVENTION OF NEONATAL NECROTIZING ENTEROCOLITIS
复制标题
DOI：
10.1016/s0022-3476(76)80553-7
复制
发表时间：
1976-01-01
影响因子：
5.1
通讯作者：
EITZMAN, DV
中科院分区：
文献类型：
--
作者：
EGAN, EA;MANTILLA, G;EITZMAN, DV
在一项前瞻性研究中，给予卡那霉素15 mg/kg/d预防新生儿坏死性小肠结肠炎。出生体重小于1500 g的新生儿存活至在佛罗里达大学[美国]新生儿重症监护室开始食物营养治疗，根据医院编号的最后一位数字将其送入对照组或研究组。消化道卡那霉素未被吸收;测定的所有血液水平均低于0.5 μ g/ml。两组的胎龄、出生体重、新生儿疾病的严重程度和治疗程序的频率相似。在研究组的35名婴儿中，没有发生新生儿坏死性小肠结肠炎，而在40名对照婴儿中发生5例（P = 0.038）。
Alimentary kanamycin, 15 mg/kg per day, was given as prophylaxis for neonatal necrotizing enterocolitis in a prospective study. Newborn infants of less than 1500 g birth weight who survived until initiation of alimentary nutrition at the University of Florida [USA] Neonatal Intensive Care Unit were admitted to a control or study group based on the last digit of the hospital number. Alimentary kanamycin was not absorbed; all blood levels determined were less than 0.5 .mu.g/ml. The 2 groups had similar gestational ages, birth weights, severity of neonatal illness and frequency of therapeutic procedures. In the study group of 35 infants, none developed neonatal necrotizing enterocolitis, whereas 5 cases occurred in the 40 control infants (P = 0.038).